|
|
|
| Clinical effect of protein nutrition support combined with antiviral therapy in HBV-related decompensated liver cirrhosis |
| YU Hong GU Shensen WANG Liying LI Xiaopeng TU Erhong Jiang·Tuxun |
| Digestive Vascular Surgery Center, the First Affiliated Hospital of Xinjiang Medical University, Xinjiang Uygur Autonomous Region, Urumqi 830011, China |
|
|
|
Abstract Objective To observe the clinical efficacy of protein nutrition support combined with antiviral therapy in Hepatitis B virus (HBV) related decompensated liver cirrhosis. Methods From March 2017 to March 2019, 112 cases with HBV decompensated liver cirrhosis of hepatitis B combined with malnutrition who admitted to the First Affiliated Hospital of Xinjiang Medical University were selected as study objects. They were divided into the observation group (56 cases) and the control group (56 cases) according to random number table method. The control-group was treated with routine antiviral therapy, and the observation group was treated with antiviral combined with protein nutrition diet. The levels of hepatitis B virus dexoyribonucleic acid (HBV-DNA), alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin (ALB), total bilirubin (TBil), liver function Child-Turcotte-Pugh (CTP) score, hyaluronic acid (HA), laminin (LN), type Ⅲ procollagen (PCⅢ), type Ⅵ collagen (Ⅵ-C) were compared, and the improvement of ascites and HBV-DNA negative rate between the two groups were compared. Results Before treatment, there were no statistically significant differences in HBV-DNA, TBil, ALT, AST, HA, LN, PCⅢ, Ⅵ-C, ALB level and CTP score between two groups (P > 0.05). After treatment, HBV-DNA, TBil, ALT, AST, HA, LN, PCⅢ, Ⅵ-C levels and CTP scores of the observation group were lower than those before treatment, and the observation group was lower than the control group (all P < 0.05). After treatment, ALB levels in two groups were higher than those before treatment, and the observation group was higher than the control group (all P < 0.05). The HBV-DNA negative conversion rate and ascites improvement rate in the observation group were higher than those in the control group (all P < 0.05). There were no statistically significant differences in the incidence of complications between the two groups (P > 0.05). Conclusion Patients in the decompensated liver cirrhosis of hepatitis B are treated with protein nutrition diet and antiviral therapy can effectively improve the liver function, inhibit the progress of liver fibrosis, promote the negative of HBV-DNA, improve the nutritional status and reduce ascites in patients with liver cirrhosis.
|
|
|
|
|
|
[1] 林春蕾，王岩，李涛，等.接受抗病毒治疗的代偿期乙肝肝硬化患者进展为肝癌的危险因素分析[J].山东医药，2017，57（32）：81-83.
[2] 邓泽润，郑嵘炅，唐莉，等.失代偿期慢性乙型肝炎肝硬化患者医院感染的相关因素分析及预防策略[J].中西医结合肝病杂志，2017，27（1）：34-36.
[3] 王婷，马臻，其其格.营养相关指标预测肝硬化失代偿期患者预后的模型建立及研究[J].现代消化及介入诊疗，2019，24（2）：95-99.
[4] 魏新亮，史晓盟，苏振华.抗病毒治疗在丙型肝炎失代偿期肝硬化患者的临床应用及其对瘦素和脂连蛋白的影响[J].山西医药杂志，2017，46（17）：2041-2045.
[5] 刘丽，江颖仪，刘景.不同Child-Pugh分级慢性乙型肝炎肝硬化患者糖代谢、胰岛素分泌情况及其与炎症反应的相关性分析[J].临床肝胆病杂志，2020，36（2）：324-328.
[6] 中华医学会肝病学分会，中华医学会感染病学分会.慢性乙型肝炎防治指南（2015年版）[J].实用肝脏病杂志，2016，19（3）：389-400.
[7] 许静涌，蒋朱明.2015年ESPEN营养不良（不足）诊断共识、营养风险及误区[J].中华临床营养杂志，2016，24（5）：261-265.
[8] 谢宇端，韩艳，高原小雪.荧光定量聚合酶链反应检测慢性乙肝患者HBV DNA的意义[J].标记免疫分析与临床，2020，27（3）：513-517，527.
[9] 曹灵芝，王靖.慢乙肝患者血清肝功能指标、HBV 标志物定量与肝组织病理学改变的关系[J].山东医药，2014， 13（19）：40-42.
[10] 凌利芬，赵洁，李振华，等.比色法与电泳法在不同疾病中检测血清白蛋白及白蛋白/球蛋白的比较分析[J].现代医学，2015，43（9）：1175-1177.
[11] 黎村艳，段贞，朱雅祺，等.壳多糖酶3样蛋白1、层粘连蛋白、Ⅳ型胶原在乙型肝炎病毒相关肝硬化中的诊断价值[J].国际检验医学杂志，2019，40（15）：1807-1810.
[12] 刘国旺，唐克诚，李谦，等.老年非活动性乙肝病毒携带者营养风险的影响因素分析[J].国际病毒学杂志，2017， 24（5）：339-342.
[13] 赵艳.拉米夫定联合安络化纤丸治疗乙肝肝硬化临床观察[J].中国医药导报，2016，13（6）：170-173.
[14] 路振宇，朱孝轩.宽胸散结和胃通腑法在代偿期肝硬化抗肝纤维化治疗过程中的运用体会[J].河北中医药学报，2017，32（5）：25-26，31.
[15] 邢乐康，邓永东，姚立琼，等.乙型肝炎肝硬化患者肠道菌群变化研究[J].实用肝脏病杂志，2020，23（2）：256-259.
[16] 王小琴，杨小丽.乙型肝炎肝硬化合并肝性脑病的危险因素[J].肝脏，2019，24（11）：1328-1329，1334.
[17] 何志颖，王冰琼，尤红.肝硬化失代偿的逆转：再代偿[J].中华肝脏病杂志，2019，27（12）：915-918.
[18] 王燕灵.失代偿期乙型肝炎肝硬化应用拉米夫定联合合理营养规划的临床疗效与预后分析[J].中国医学前沿杂志，2014，6（6）：119-121.
[19] Jindal A，Jagdish RK. Sarcopenia：Ammonia metabolism and hepatic encephalopathy [J]. Clin Mol Hepatol，2019， 25（3）：270-279.
[20] 萧雍江.用恩替卡韦对乙型肝炎肝硬化失代偿期患者进行治疗的效果探讨[J].当代医药论丛，2019，17（18）：112-113.
[21] 中华医学会肝病学分会，中华医学会消化病学分会.终末期肝病临床营养指南[J].实用肝脏病杂志，2019，22（5）：624-635.
[22] 史志红，周晓，班志芬.乙型肝炎肝硬化与酒精性肝硬化患者营养状况评估分析[J].实用肝脏病杂志，2018， 21（4）：629-630.
[23] 梁明霞.拉米夫定联合合理营养规划治疗失代偿期乙型肝炎肝硬化临床观察[J].北方药学，2016，13（6）：108-109.
[24] 周秀琳.饮食干预对失代偿期肝硬化患者营养状况的影响[J].现代中西医结合杂志，2011，20（13）：1608-1609.
[25] 徐京杭，徐小元.肝硬化临床研究进展和未满足的需求[J].中华肝脏病杂志，2019，27（12）：913-914. |
|
|
|
